VKTX Viking Therapeutics Inc

$39.11

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Viking Therapeutics, with a market cap of approximately $3.77 billion, is poised for its upcoming earnings announcement on October 22, 2025, amidst a backdrop of anticipation and strategic potential. Despite the EPS and revenue estimates both standing at $0.00, the whisper number aligns with these projections, suggesting that market expectations are tempered, likely due to the company's current focus on long-term strategic initiatives rather than immediate financial performance. This biopharmaceutical company, known for its innovative approach to developing therapies for metabolic and endocrine disorders, may not be showcasing immediate revenue gains, but its robust pipeline and ongoing clinical trials could be pivotal in shaping future growth. Investors will be keenly observing any updates on these developments, as they hold the potential to significantly impact Viking's market positioning and investor sentiment in the long run.

Updated On 11/14/2025

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.

Website: https://www.vikingtherapeutics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1607678
Address
12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, US
Valuation
Market Cap
$2.69B
P/E Ratio
nan
PEG Ratio
-0.03
Price to Book
3.05
Performance
EPS
$-1.01
Dividend Yield
—
Profit Margin
0.00%
ROE
-17.90%
Technicals
50D MA
$27.47
200D MA
$47.72
52W High
$81.86
52W Low
$18.92
Fundamentals
Shares Outstanding
112M
Target Price
$95.44
Beta
0.83

VKTX EPS Estimates vs Actual

● Estimated
● Actual

VKTX News & Sentiment

Nov 14, 2025 • Zacks Commentary NEUTRAL
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Nov 12, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is It Worth Investing in Viking Therapeutics ( VKTX ) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Nov 12, 2025 • Zacks Commentary NEUTRAL
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Nov 12, 2025 • Benzinga NEUTRAL
AMD, OKLO, APP, VKTX, NVO: 5 Trending Stocks Today - Advanced Micro Devices ( NASDAQ:AMD )
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30. These are the top stocks that gained the attention of retail traders and investors ...
Nov 11, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Nov 10, 2025 • Zacks Commentary NEUTRAL
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
Sentiment Snapshot

Average Sentiment Score:

0.184
50 articles with scored sentiment

Overall Sentiment:

Bullish

VKTX Reported Earnings

Jul 23, 2025
Jun 30, 2025 (Post market)
-0.14 Surprise
  • Reported EPS: $-0.58
  • Estimate: $-0.44
  • Whisper: —
  • Surprise %: -31.8%
Apr 23, 2025
Mar 31, 2025 (Post market)
-0.1 Surprise
  • Reported EPS: $-0.41
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -32.3%
Feb 05, 2025
Dec 31, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: -18.5%
Oct 23, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 12.0%
Jul 24, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: 25.9%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 7.1%
Feb 07, 2024
Dec 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 0.0%
Oct 25, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.22
  • Whisper: —
  • Surprise %: -4.5%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.19
  • Whisper: —
  • Surprise %: 0.0%

Financials